Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. - Wikidata - awgldk - TriplyDB

Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.

Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.

http://www.wikidata.org/entity/Q37771144

about

Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro.Noscapine recirculates enterohepatically and induces self-clearance.Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.Application of the DataChip/MetaChip technology for the evaluation of ajoene toxicity in vitro.Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.Characterization of xenobiotic-induced hepatocellular enzyme induction in rats: anticipated thyroid effects and unique pituitary gland findings.Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction.

P2860

Q35873088-7472E2C2-AEB2-42C2-B90A-AF3BD36FE8C5 Q35893886-F8DC8FBE-93D6-464B-88BD-A896F0FD0EC3 Q37607932-A1ED9C54-344B-42A1-AD75-0A799C7C39B2 Q38774776-D5FC3EE6-9E31-4FE4-92C5-38B88E83BEC6 Q44740396-CD3F7DD8-3A2A-4CA8-8097-11BDAC75CB7A Q47565453-FE1E4424-9288-49AD-AF73-7BB5252D5CF4 Q51466740-838EB969-069C-4459-8752-3EC00575131C Q53804885-9EECD1A3-BFCA-4760-A16E-EDF263F2A8A2

P2860

Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.

http://www.wikidata.org/entity/Q37771144

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 July 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hepatic drug-metabolizing enzy ...... and clinical risk assessment.

@en

Hepatic drug-metabolizing enzy ...... and clinical risk assessment.

@nl

type

label

Hepatic drug-metabolizing enzy ...... and clinical risk assessment.

@en

Hepatic drug-metabolizing enzy ...... and clinical risk assessment.

@nl

prefLabel

Hepatic drug-metabolizing enzy ...... and clinical risk assessment.

@en

Hepatic drug-metabolizing enzy ...... and clinical risk assessment.

@nl

P1433

Q37771144-92C5D236-6CEC-40CD-962E-035EDD20E714

P1476

Q37771144-34F6F801-D9CD-4E14-AA28-51FF0CF3C9B8

P2093

Q37771144-1BA0BF55-995C-4D89-AEEE-2667422439A2

Q37771144-22D7BE63-8758-4886-A1B1-49D07E13F4B1

Q37771144-52DB6FCF-6318-4A3A-B917-946A70474D36

Q37771144-60A59A34-ED68-4428-9B33-A87B96CA1EE6

Q37771144-9478BAD3-6DE9-4FB9-BC31-B0BB4A624909

Q37771144-98D7E195-D7BF-4A45-AA3F-F3D25744F405

P2860

Q37771144-02FE8818-CDF3-4C50-A328-AEF1914F30F9

Q37771144-08B9AB0C-128C-4D3E-8EA0-ADF12ED14EB7

Q37771144-095BC183-DF2C-4807-9B9B-B3F3893C9B46

Q37771144-0C105DC1-C7B8-4577-8505-1BBB712AAA0C

Q37771144-1B3DD667-D67F-451A-B4D6-0E196B5FA18B

Q37771144-1E5C839A-F005-4BFF-A454-3B85A271D3B7

Q37771144-22FD237F-D5C5-40E6-BB22-42EEB48B52A5

Q37771144-27D47E9F-D7A8-4EDB-AED0-368429D1513E

Q37771144-2CA5E771-83E6-4EF2-9240-73FA1FAFE2C5

Q37771144-2D34B049-BF9D-436A-BD83-13A3F2079905

P304

Q37771144-6E90C72F-4A9C-4861-BA44-DA65B603C04C

P31

Q37771144-D23F9FDA-D5C8-4B73-9949-04CF43CF5F3C

P356

Q37771144-AE9D4D52-7D54-48E2-B570-00EDDC62EE64

P407

Q37771144-350FCBE4-6370-4D13-8D4E-E8E6E91E6FB7

P433

Q37771144-ADEF4A9E-BE2E-4E84-B7C6-4249E9AD0383

P478

Q37771144-C6D200FC-6BD6-4D2E-A94C-32E3FD342738

P577

Q37771144-B5AD74E6-80EC-405B-8B7D-C4EA6586F0BF

P5875

Q37771144-570F6405-1A3C-4A70-A364-EB630E9B033A

P698

Q37771144-FD9CFC79-A115-41AC-8E52-16BA1EFBB611

P356

0192623310375099

P1433

Toxicologic Pathology

P1476

Hepatic drug-metabolizing enzy ...... and clinical risk assessment.

@en

P2093

Annette Romeike

http://www.w3.org/2001/XMLSchema#string

John Fowler

http://www.w3.org/2001/XMLSchema#string

Michael A Mohutsky

http://www.w3.org/2001/XMLSchema#string

Sabine Francke-Carroll

http://www.w3.org/2001/XMLSchema#string

Vince Meador

http://www.w3.org/2001/XMLSchema#string

William M Lee

http://www.w3.org/2001/XMLSchema#string

P2860

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study

Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor

Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68.

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

An integrated functional genomic study of acute phenobarbital exposure in the rat

Effects of hepatic drug-metabolizing enzyme induction on clinical pathology parameters in animals and man.

Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

P304

799-809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0192623310375099

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45113915

http://www.w3.org/2001/XMLSchema#string

P698

20616377

http://www.w3.org/2001/XMLSchema#string